Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Assets (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Assets for 6 consecutive years, with $494.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets changed N/A year-over-year to $494.9 million, compared with a TTM value of $494.9 million through Sep 2025, changed N/A, and an annual FY2024 reading of $499.5 million, up 1.02% over the prior year.
  • Assets was $494.9 million for Q3 2025 at Cytek Biosciences, roughly flat from $493.3 million in the prior quarter.
  • Across five years, Assets topped out at $525.1 million in Q2 2023 and bottomed at $230.3 million in Q2 2021.
  • Average Assets over 5 years is $479.2 million, with a median of $494.5 million recorded in 2023.
  • The sharpest move saw Assets surged 114.01% in 2022, then decreased 6.2% in 2024.
  • Year by year, Assets stood at $463.3 million in 2021, then rose by 12.12% to $519.5 million in 2022, then fell by 4.82% to $494.5 million in 2023, then increased by 1.02% to $499.5 million in 2024, then dropped by 0.92% to $494.9 million in 2025.
  • Business Quant data shows Assets for CTKB at $494.9 million in Q3 2025, $493.3 million in Q2 2025, and $499.5 million in Q4 2024.